New hope for tough myasthenia gravis cases? eculizumab trial in china

NCT ID NCT06764160

Completed Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 study tested eculizumab in 15 Chinese patients with refractory generalized myasthenia gravis (gMG), a condition where standard treatments fail. Eculizumab is given by IV infusion and aims to improve daily living activities and muscle strength. The study measured changes in symptom scores over 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eculizumab
What this could lead to: If successful, this could provide a new treatment option for Chinese patients with hard-to-control generalized myasthenia gravis.
What could go wrong: This is a small, single-arm study with only 15 participants, so results may not apply broadly. Eculizumab can increase risk of serious infections, including meningitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS (GMG) REFRACTORY GMG

Contacts and locations

Locations

Research Site

Changchun, 130021, China
Research Site

Fuzhou, 350001, China
Research Site

Guangzhou, 510080, China
Research Site

Guangzhou, 510620, China
Research Site

Qingdao, 266035, China
Research Site

Shanghai, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.